U.S. market Closed. Opens in 5 hours 53 minutes

INZY | Inozyme Pharma, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
RevenueN/AN/AN/AN/AN/AN/A
Cost of Revenue1.29M1.18M1.05M217.00K83.00KN/A
Gross Profit-1.29M-1.18M-1.05M-217.00K-83.00KN/A
Operating Expenses75.64M68.67M56.65M57.04M20.81M11.59M
Selling, General & Admin20.80M20.83M18.93M10.55M4.59M3.49M
Research & Development54.85M47.85M37.72M46.49M16.22M8.10M
Other Operating ExpensesN/A-319.00K-189.00K247.00K-24.00K4.34M
Operating Income-75.64M-68.67M-56.65M-57.04M-20.81M-11.59M
Other Expenses / Income4.48M1.61M22.00K617.00K1.08M4.34M
Before Tax Income-71.17M-67.06M-56.62M-56.42M-19.72M-6.96M
Income Tax ExpensesN/A-1.61M-211.00K-587.00K-1.11M4.63M
Net Income-71.17M-65.45M-56.41M-55.84M-18.62M-6.96M
Interest Expenses3.33M-1.61MN/AN/AN/AN/A
Basic Shares Outstanding51.84M37.76M23.56M23.38M15.16M15.14M
Diluted Shares Outstanding51.84M37.76M23.56M23.38M15.16M15.14M
EBITDA-74.81M-68.67M-55.97M-57.04M-20.72M-11.57M
EBITDA Margin0.00%0.00%0.00%0.00%0.00%0.00%
EBIT-67.84M-68.67M-56.62M-56.42M-19.72M-2.33M
EBIT Margin0.00%0.00%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙